Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Comparison of Guselkumab vs Secukinumab in Moderate to Severe Plaque Psoriasis
2016-002995-29Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of guselkumab, secukinumab in psoriasis, sponsored by Janssen Pharmaceutical. Started Feb 2017; status: completed.
02
Drugs
guselkumabsecukinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2016-002995-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002995-29.